UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported): March 31, 2008


VioQuest Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 


Delaware
000-16686
58-1486040
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)



180 Mt. Airy Road
Basking Ridge, NJ 07920
(Address of principal executive offices)


(908)766-4400
(Registrant's telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 



Item 2.02  Results of Operations and Financial Condition.

On March 31, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) issued a press issued release announcing its financial results for the year ended December 31, 2007. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith.

 Exhibit No.
 
Description
99.1
 
VioQuest Pharmaceuticals, Inc. press release dated March 31, 2008.



 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VioQuest Pharmaceuticals, Inc.
      
        
        
Date: March 31, 2008
By: 
/s/ Brian Lenz
   
Brian Lenz
   
Chief Financial Officer

 
 
 


EXHIBIT INDEX

Ex. No.
Description
 
    
99.1
VioQuest Pharmaceuticals, Inc. press release dated March 31, 2008.